Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Kabi“
Suchtreffer
Begriffe & Kennungen
Bortezomib Fresenius Kabi · 4.8 · Peripheral neuropathy in combination regimens Multiple myeloma In trials in which bortezomib was administered
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Peripheral neuropathy in combination regimens Multiple myeloma In trials in which bortezomib was administered
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Retreatment of patients with relapsed multiple myeloma In a study in which bortezomib retreatment was administ
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Retreatment of patients with relapsed multiple myeloma In a study in which bortezomib retreatment was administ
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Summary of the safety profile Serious adverse reactions uncommonly reported during treatment with bortezomib i
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Summary of the safety profile Serious adverse reactions uncommonly reported during treatment with bortezomib i
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Table 10: Incidence of peripheral neuropathy in study LYM-3002 by toxicity and treatment discontinuation due t
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Table 7: Adverse reactions in patients with multiple myeloma treated with bortezomib in clinical trials and al
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Table 8: Adverse reactions in patients with mantle cell lymphoma treated with BR-CAP in a clinical trial Syste
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Table 8: Adverse reactions in patients with mantle cell lymphoma treated with BR-CAP in a clinical trial Syste
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Table 9: Incidence of peripheral neuropathy during induction treatment by toxicity and treatment discontinuati
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Tabulated list of adverse reactions Multiple myeloma Undesirable effects in table 7 were considered by the inv
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Tabulated list of adverse reactions Multiple myeloma Undesirable effects in table 7 were considered by the inv
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · The incidence of death on treatment was 5% in the subcutaneous treatment group and 7% in the intravenous treat
Eintrag öffnenBusulfan Fresenius Kabi
Eintrag öffnenBusulfan Fresenius Kabi · 4.1 Therapeutic indications · 1
Eintrag öffnenBusulfan Fresenius Kabi · 4.3 Contraindications · 1
Eintrag öffnenBusulfan Fresenius Kabi · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Pregnancy (see sec
Eintrag öffnen